Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Enterprise Value (2020 - 2026)

Apellis Pharmaceuticals filings provide 6 years of Enterprise Value readings, the most recent being -$467.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 13.36% year-over-year to -$467.7 million, compared with a TTM value of -$467.7 million through Dec 2025, down 13.36%, and an annual FY2025 reading of -$467.7 million, down 13.36% over the prior year.
  • Enterprise Value hit -$467.7 million in Q4 2025 for Apellis Pharmaceuticals, up from -$480.6 million in the prior quarter.
  • The five-year high for Enterprise Value was -$267.0 million in Q1 2021, with the low at -$852.8 million in Q2 2022.
  • Median Enterprise Value over the past 5 years was -$441.9 million (2021), compared with a mean of -$489.4 million.
  • The sharpest move saw Enterprise Value soared 67.3% in 2021, then tumbled 213.11% in 2022.
  • Year by year, Enterprise Value stood at -$700.6 million in 2021, then rose by 21.05% to -$553.1 million in 2022, then surged by 36.3% to -$352.3 million in 2023, then fell by 17.12% to -$412.6 million in 2024, then fell by 13.36% to -$467.7 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$467.7 million, -$480.6 million, and -$371.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.